One-Shot gene therapy trial aims to fix copper poisoning disease
NCT ID NCT07173933
Summary
This is an early-stage trial testing a new, one-time gene therapy called GC310 for adults with Wilson's Disease. The main goals are to find a safe dose and see if the treatment helps the body properly manage copper, which builds up to toxic levels in this condition. About 15 participants will receive the therapy and be monitored closely for one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College
Beijing, 100005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.